Keyphrases
Europe
100%
Neuroblastoma
100%
High-dose Therapy
100%
Melphalan
50%
Age Groups
25%
First Remission
25%
Remission Status
25%
Busulphan
25%
High Risk
12%
Multivariate Analysis
12%
Age at Diagnosis
12%
Randomized Trial
12%
Young Patients
12%
Allogeneic
12%
Event-free Survival
12%
Single High Dose
12%
Peripheral Stem Cells
12%
Stable Disease
12%
Partial Remission
12%
Autologous Stem Cell Rescue
12%
Marrow Transplantation
12%
Autologous SCT
12%
Sensitive Relapse
12%
Nursing and Health Professions
Drug Megadose
100%
Neuroblastoma
100%
Remission
62%
Melphalan
50%
Busulfan
25%
Multivariate Analysis
12%
Event Free Survival
12%
Patient with Neuroblastoma
12%
Diseases
12%
Pharmacology, Toxicology and Pharmaceutical Science
Remission
100%
Neuroblastoma
100%
Melphalan
80%
Busulfan
40%
Event Free Survival
20%
Diseases
20%
Medicine and Dentistry
Drug Megadose
100%
Ganglioneuroblastoma
100%
Melphalan
50%
Stem Cell
25%
Busulfan
25%
Multivariate Analysis
12%
Event Free Survival
12%
Patient with Neuroblastoma
12%
Diseases
12%
Agricultural and Biological Sciences
Progenitor Cell
100%
Multivariate Analysis
50%